Results 21 to 30 of about 62,786 (347)

NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance

Technology in Cancer Research & Treatment, 2022
Background: The study aims to detect the expression of Na + /taurocholate cotransporter polypeptide in hilar cholangiocarcinoma of rat model, to provide a new therapeutic target for gene therapy of hilar cholangiocarcinoma.
Meng-yu Zhang MD, Ming Luo MD, Kai He MD, Xian-ming Xia MD, Jie-ping Wang MD   +4 more
doaj   +1 more source

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations

Journal of Diabetes Investigation, 2023
The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger‐onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β‐cell
Jaime A Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed, Zanariah Hussein   +4 more
doaj   +1 more source

Regulation of the Renal NaCl Cotransporter and Its Role in Potassium Homeostasis.

Physiological Reviews, 2020
Daily dietary potassium (K+) intake may be as large as the extracellular K+ pool. To avoid acute hyperkalemia, rapid removal of K+ from the extracellular space is essential.
E. Hoorn, Martin Gritter, Catherina A. Cuevas, R. Fenton   +3 more
semanticscholar   +1 more source

Regulators of Slc4 bicarbonate transporter activity

Frontiers in Physiology, 2015
The Slc4 family of transporters is comprised of anion exchangers (AE1-4), Na-coupled bicarbonate transporters (NCBTs) including electrogenic Na/bicarbonate cotransporters (NBCe1 and NBCe2), electroneutral Na/bicarbonate cotransporters (NBCn1 and NBCn2 ...
Ian M. Thornell, Mark Oliver Bevensee
doaj   +1 more source

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Cardiovascular Diabetology, 2020
Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the ...
M. Arow, M. Arow, M. Waldman, M. Waldman, Dor Yadin, Dor Yadin, V. Nudelman, A. Shainberg,, Nader G. Abraham, D. Freimark, Ran Kornowski, D. Aravot, E. Hochhauser, Michael Arad   +13 more
semanticscholar   +1 more source

Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study

Journal of Diabetes Investigation, 2022
The present retrospective study aimed to identify factors associated with an increased risk of acute kidney injury in Japanese patients with type 2 diabetes treated with sodium–glucose cotransporter 2 inhibitors.
Takeshi Horii, Yoichi Oikawa, Narumi Kunisada, Akira Shimada, Koichiro Atsuda   +4 more
doaj   +1 more source

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Circulation, 2016
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight.
H. Heerspink, B. Perkins, D. Fitchett, M. Husain, D. Cherney   +4 more
semanticscholar   +1 more source

K+/Cl− cotransporter 2 (KCC2) and Na+/HCO3− cotransporter 1 (NBCe1) interaction modulates profile of KCC2 phosphorylation

Frontiers in Cellular Neuroscience, 2023
K+/Cl− cotransporter 2 (KCC2) is a major Cl− extruder in mature neurons and is responsible for the establishment of low intracellular [Cl−], necessary for fast hyperpolarizing GABAA-receptor mediated synaptic inhibition.
Abhishek Pethe, Mira Hamze, Marina Giannaki, Bernd Heimrich, Igor Medina, Anna-Maria Hartmann, Anna-Maria Hartmann, Eleni Roussa   +7 more
doaj   +1 more source

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Diabetes Care, 2019
Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in ...
T. Danne, S. Garg, A. Peters, J. Buse, C. Mathieu, J. Pettus, C. Alexander, T. Battelino, F. Ampudia-Blasco, B. Bode, B. Cariou, Kelly L Close, P. Dandona, S. Dutta, E. Ferrannini, S. Fourlanos, G. Grunberger, S. Heller, R. Henry, Martin J. Kurian, J. Kushner, T. Oron, T. Oron, C. Parkin, T. Pieber, H. Rodbard, D. Schatz, J. Skyler, W. Tamborlane, K. Yokote, M. Phillip, M. Phillip   +31 more
semanticscholar   +1 more source

Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria

Терапевтический архив, 2020
Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal ...
N. V. Sturov, S. V. Popov, N. K. Mamporia, A. A. Mager   +3 more
doaj   +1 more source